
FDA Approves Treprostinil Inhalation Powder to Expand Treatment for PAH and PH-ILD
The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog designed to enhance exercise capacity in adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with …